Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 3Withdrawn 2Not yet recruiting 2Unknown 1Suspended 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 8Colorectal Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mouth Neoplasms 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Liposarcoma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 3venetoclax 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2calaspargase pegol 2auricularum 2Vincristine 2Thioguanine 2Specimen Handling 2Methotrexate 2Mercaptopurine 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Daunorubicin 2Cytarabine 2Cyclophosphamide 2Calcium Dobesilate 2Bortezomib 2Biopsy 2Asparaginase 2revumenib 1prednylidene 1pegaspargase 1nelarabine 1exifone 1deltacortene 1capivasertib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Biopsy × Clear all
NCT07636564 2026-06-09

Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment

SWOG Cancer Research Network

Phase 2 Not yet recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡